AGENDA Access Pre/Post Tests and Presentations: PennMedicine.org/Abramson/BloodCME Password: Blood2018 (case sensitive) For Free Wi-Fi use HHonors Promotion Code: phlph2218 7:30 am Registration and Continental Breakfast 8:00 am Welcome and Introduction Edward A Stadtmauer, MD Ellen Rubesin, Executive Director, Leukemia & Lymphoma Society KEYNOTE PRESENTATION 8:10 am Actualizing Cellular Therapies for Hematologic Malignancies Edward A Stadtmauer, MD and Patricia Mangan, MSN, CRNP NEW THERAPIES AND CURRENT MANAGEMENT OF LYMPHOMAS MODERATOR: Stephen J Schuster, MD 9:00 am New Therapies and Current Management of Follicular Lymphomas Stephen J Schuster, MD 9:30 am Therapeutic Advances in Hodgkin s and T-Cell Lymphoma Jakub Svoboda, MD 10:00 am Large Cell Lymphoma and Aggressive Lymphomas Sunita D Nasta, MD, FACP 10:30 am Case Presentation with Panel Discussion MODERATOR: Daniel J Landsburg, MD PANEL: Danielle Land, MSN, CRNP Sunita D Nasta, MD, FACP Jakub Svoboda, MD Stephen J Schuster, MD 11:15 am BREAK UPDATE ON TREATMENT STRATEGIES IN LEUKEMIA MODERATOR: Selina M Luger, MD 11:25 am Update in Treatment Strategies for ALL and AML Shannon R McCurdy, MD
11:55 am Update in Myeloproliferative Disease Daria V Babushok, MD, PHD 12:20 pm Emerging Treatment Options for Myelodysplastic Syndromes James K Mangan, MD, PhD 12:40 pm Panel Discussion with Question and Answer Session MODERATOR: Selina M Luger, MD PANEL: Daria V Babushok, MD, PhD Marie Block, MSN, CRNP James K Mangan, MD, PhD Shannon R McCurdy, MD 1:10 pm Lunch and Network JOIN A SPECIAL INTEREST LUNCH TABLE Talk with an expert and network with colleagues TOPICS INCLUDE: Cellular Therapy Garfall/Cohen Stem Cell/Bone Marrow Transplantation Frey Immuno-compromised Patient Mangan J Toxicities Mangan P Chronic Lymphocytic Lymphoma Schuster/Svoboda Pharmacology in the Geriatric Patient Nasta Late Effects for Survivors McCurdy Economics of Cellular Therapies (Pharmacist) Ganetsky, Alex Open Networking Talk with a Physician, Nurse, Pharmacist 2:00 pm Update in Bone Marrow and Stem Cell Transplantation Noelle V Frey, MD, MSCE CONTROVERSIES AND UPDATE IN MULTIPLE MYELOMA MODERATOR: Edward A Stadtmauer, MD 2:30 pm Initial Therapy for Multiple Myeloma Including Transplant Alfred L Garfall, MD, MTR 3:00 pm Experimental Therapies for Relapsed Myeloma Dan T Vogl, MD, MSCE 3:30 pm Role of Immunotherapy for Myeloma Adam D Cohen, MD 4:00 pm Case Presentation with Panel Discussion MODERATOR: Edward A Stadtmauer, MD PANEL Stephen G Wallace, MD Adam D Cohen, MD Alfred L Garfall, MD 4:30 pm Evaluation and Adjourn Patricia Mangan, MSN, CRNP Dan T Vogl, MD, MSCE
Post Conference Details After the conference has concluded, all healthcare professionals will receive an email from the Office of Continuing Medical and Interprofessional Education containing instructions on where to find the conference evaluation and request a certificate. Once participants submit the request for credit, the certificate can be viewed on a transcript or a certificate can be printed by logging onto penncmeonline.com. Program Overview This conference is a comprehensive review of hematologic malignancies focusing on the clinical application of new research developments over the preceding year. Didactic presentations will include case discussions with Penn faculty and community experts. The conference format will provide significant opportunity for interaction with expert faculty and other attendees. Participants will leave with up-to-date, practical information which will have immediate clinical application. Target Audience This activity has been designed for hematologists, medical and radiation oncologists, primary care physicians, pathologists, hematology/oncology fellows, oncology nurses, oncology social workers, and other healthcare professionals involved in the treatment of patients with blood cancer. Learning Objectives Upon completion of this course, participants should be able to: Discuss clinical features, including differential diagnoses for the various hematologic malignancies Describe recent advances in treatment for the various hematologic malignancies Summarize the major patient management issues experienced by the interprofessional care team associated with hematologic malignancies Define the state-of-the-art for genomic analyses for hematologic malignancies Apply new strategies for incorporating therapies that target metabolism in blood cancers Accreditation In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Designation of Credit PHYSICIANS: Penn Medicine designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. NURSES: The program will award 8.25 contact hours. PHYSICIAN ASSISTANTS: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 8.25 Category 1 credits for completing this activity.
Acknowledgement of Commercial Support We Gratefully Acknowledge the Following Organizations for Providing Educational Grants in Support of This Continuing Medical Education Activity AbbVie Gilead Sciences Merck Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Takeda Oncology EXHIBITOR AbbVie Adaptive Biotechnologies Agios Pharmaceuticals Alexion Pharmaceuticals Amgen AstraZeneca Bristol-Myers Squibb Celgene Foundation Medicine Genentech Gilead Sciences Incyte Ipsen Janssen Jazz Pharmaceuticals Kite Pharma Merck Novartis Pharmaceuticals Pfizer Pharmacyclics Seattle Genetics Spectrum Pharmaceuticals Takeda Oncology Teva Pharmaceutical
Penn Medicine Speakers Edward A Stadtmauer, MD Course Director Roseman, Tarte, Harrow, and Shaffer Families President s Distinguished Professor Chief, Hematologic Malignancies Section Division of Hematology Oncology Co-Leader, Hematologic Malignancies Research Program Selina M Luger, MD Course Co-Director Professor, Medicine Division of Hematology Oncology Director, Leukemia Program David L Porter, MD Course Co-Director Jodi Fisher Horowitz Professor of Leukemia Care Excellence Division of Hematology Oncology Director, Blood and Marrow Transplantation Stephen J Schuster, MD Course Co-Director Robert and Margarita Louis-Dreyfus Associate Professor of Chronic Lymphocytic Leukemia and Lymphoma Division of Hematology Oncology Director, Lymphoma Program and Lymphoma Translational Research Daria V Babushok, MD, PhD Instructor of Medicine Marie Block, MSN, CRNP Nurse Practitioner of Medicine Adam D Cohen, MD Noelle V Frey, MD, MSCE Alex Ganetsky, PharmD Hematology/Oncology Clinical Pharmacy Specialist Alfred L Garfall, MD, MTR Danielle Land, MSN, CRNP Nurse Practitioner of Medicine Daniel J Landsburg, MD James K Mangan, MD, PhD Patricia Mangan, MSN, CRNP Nurse Practitioner of Medicine Shannon R McCurdy, MD Sunita D Nasta, MD, FACP Associate Professor of Medicine Jakub Svoboda, MD Dan T Vogl, MD Stephen G Wallace, MD Clinician, Hematology Oncology Penn Medicine at Virtua
Cynthia L. Griffo, MS, RN Director, Communications and Education Penn s Abramson Cancer Center Barbara Lopez Senior Education and Outreach Coordinator Penn s Abramson Cancer Center PLANNING COMMITTEE MEMBERS DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS It is policy at Penn Medicine for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provides products or services that may be relevant to the content of this continuing medical education activity. For this purpose, we consider relationships of the person involved in the CME activity to include financial relationships of a spouse or partner. The intent of this policy is to ensure that Penn CME/CNE-certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information provided to the Penn Office of CME was found to contain relationships that created a conflict of interest relative to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations. Staff in the Office of CME at the Perelman School of Medicine at the University of Pennsylvania (Mila Kostic, FACHEP and Belinda Rose), Planning Committee Members (Cynthia Griffo, RN, MS, Barbara Lopez) and the Senior Peer Reviewer, Zalman Agus, MD, have reported that they have no relevant financial relationships with any commercial interests related to the content of this educational activity. The following faculty has disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity: FACULTY NAME Daria V Babushok, MD, PhD Alex Ganetsky, PharmD Danielle Land, MSN, CRNP Stephen G Wallace, MD The following faculty has reported the relevant financial relationships with commercial interests related to the content of this educational activity. Faculty Name Name of Commercial Interest Relationship Marie Block, MSN, CRNP Celgene, Takeda Speaker Adam D Cohen, MD Celgene, Janssen and Bristol-Myers Squibb Advisory Board Seattle Genetics and GlaxoSmithKline Advisory Board Bristol-Myers Squibb and Novartis Research Grant Support Celgene Noelle V Frey, MD, MSCE Novartis and Servier Alfred L Garfall, MD, MS Amgen, Bioinvent and Novartis Research Grant Support Kite Pharma
Daniel J Landsburg, MD Curis and Takeda Grants/Research Support Curis Selina Luger, MD Amgen, Ariad, Celgene, Cyclacel, Incyte Grants/Research Support Janssen and Seattle Genetics Arog, Incyte and Novartis Astellas and Pfizer Advisory Board Patricia Mangan, MSN, CRNP Kite Pharma Advisory Board Sunita D Nasta, MD, FACP Allernon, DebioPharm, Immunogen and Millenium/Takeda Celgene Grants/Research Support Speakers Bureau, Advisory Board David L Porter, MD Novartis and Kite Pharma Advisory Board Novartis Grants/Research Support Genentech Spouse Employment Stephen J Schuster, MD Celgene, Genentech, Merck, Novartis, Advisory Board, Pharmacyclics, Seattle Genetics and Grants/Research Support Janssen Research Support Adaptive Research Support Gilead and Nordic Nanovector Advisory Board and Edward A Stadtmauer, MD Amgen, Celgene, Janssen, Novartis and Takeda Jakub Svoboda, MD BMS, Celgene, Merck, Pharmacyclics Grants/Research Support and Seattle Genetics BMS, Kite, Kyowa and Seattle Genetics Dan T Vogl, MD Celgene, Janssen and Karyopharm Relevant Financial Relationships: Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected. INVESTIGATIONAL AND/OR OFF-LABEL USE OF COMMERCIAL PRODUCTS AND DEVICES Penn Medicine requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications. The following faculty reported specific mentions of off-label and/or investigational use of products within their presentations.
NAME PRODUCT INVESTIGATIONAL AND/OR OFF-LABEL USE Alfred L Garfall, MD Elotuzumab Maintenance Therapy for Multiple Myeloma James K Mangan, MD CC-486, Guadecitabine, Rigosertib and Luspatercept Idhifa Investigational Off-label use Shannon R McCurdy, MD Ivosidenibe Clinical trials in relapse refractory AML and in combination with Azacitidine Enasidenibe Inotuzumab ozogamicin, Gilteritinib Clinical trials in combination with Azacitidine Published clinical trial results in combination with mini HYPERCVAD Clinical Trials Sunita D Nasta, MD, FACP Azacytadine, Brentuximab vedotin, Lymphoma Therapy Nivolumab, Pembrolizumab and Polatuzumab Stephen J Schuster, MD CAR T-cells CAR T-cells for lymphomas Edward A Stadtmauer, MD CD19 CAR Off-label Jakub Svoboda, MD Brentuximab, Nivolumab, Mogamulizumab and Pembrolizumab Investigational and Off-Label Dan T Vogl, MD Ibrutinib, KPT-8602, Selinexor Myeloma Therapy and Venetoclax Post Conference Details After the conference has concluded, all healthcare professionals will receive an email from the Office of Continuing Medical and Interprofessional Education containing instructions on where to find the conference evaluation and request a certificate. Once participants submit the request for credit, the certificate can be viewed on a transcript or a certificate can be printed by logging onto penncmeonline.com.